Real-world evidence studies conducted by CSL Seqirus have demonstrated the value of influenza vaccination in protecting public health. These studies, presented at the European Scientific Working Group on Influenza (ESWI) Conference, provide valuable insights into the clinical impact and effectiveness of different influenza vaccines.
One study focused on the clinical impact of seasonal influenza in adults between 2015 and 2020. The results showed a significant increase in pneumonia-related medical encounters with age following an influenza encounter. This suggests that the risk of developing serious flu-related complications, such as pneumonia, increases as we age. These findings emphasize the importance of conducting real-world studies to evaluate vaccine effectiveness and tailor prevention strategies for vulnerable populations.
Another study compared the effectiveness of different influenza vaccines during the 2019/20 season. The results showed that an adjuvanted inactivated trivalent influenza vaccine was more effective in preventing influenza-related medical encounters, outpatient visits, and hospitalizations among adults with cumulative risk factors compared to a high-dose inactivated trivalent influenza vaccine. The study also found comparable effectiveness of these vaccines in individuals with no high-risk conditions, highlighting the impact of innovative vaccine technologies.
A third study compared the effectiveness of cell-based quadrivalent influenza vaccines (QIVc) with traditional egg-based quadrivalent influenza vaccines (QIVe). The results showed that QIVc was more effective in preventing outpatient test-confirmed influenza over three consecutive seasons. This highlights the clinical value of cell-based vaccines, especially considering the variability of circulating influenza viruses.
These studies reinforce the importance of influenza vaccination in reducing the burden of flu-related illnesses. Vaccines remain one of the most effective tools for fighting influenza and preventing its complications. By advancing the science of influenza prevention, CSL Seqirus aims to contribute to public health and reduce the morbidity and mortality associated with influenza.
These real-world evidence studies provide valuable data on the effectiveness of influenza vaccines in different populations. They complement randomized controlled trials and contribute to an ever-growing data set on real-world outcomes, allowing for continuous evaluation and improvement of vaccine strategies.
Source:
– Study 1: Healthcare Resource Use and Complications Among Adults with an Influenza-Related Medical Encounter: 2015-2020 Influenza Seasons in the United States.
– Study 2: Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine vs High-Dose Influenza Vaccine in Older Adults with Influenza Risk Factors during the 2019-2020 U.S. Influenza Season.
– Study 3: Superior Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines Against Outpatient Test-Confirmed Influenza Over Three Consecutive Seasons in the United States.
